Every material Form 8-K Coherus Oncology, Inc. has filed with the SEC since August 17, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Coherus Oncology said on October 28, 2026 that interim data from its TREGCHECK program showed a confirmed overall response rate of 75% (6 of 8 evaluable patients) in first-line esophageal squamous cell carcinoma (ESCC) with tagmokitug, toripalimab and chemotherapy. The company plans to expand enrollment in both first-line and second-line ESCC cohorts, but the sample sizes are small and the drug is investigational and not approved.
First-line ESCC: confirmed overall response rate of 75% (6/8) as of October 14, 2026, rising to 89% (8/9) after two additional partial responses were confirmed following the data cutoff
Second-line ESCC at the 700 mg dose: clinical benefit rate of 33.3% (2/6) and confirmed overall response rate of 16.7% (1/6)
Safety: among 120 patients on tagmokitug plus toripalimab, 40% had immune-related adverse events of any grade and 20% had Grade 3-5 events; no Grade 5 treatment-related adverse events were reported
Coherus Oncology entered an at-the-market sales agreement with Leerink Partners allowing it to sell up to $50.0 million of common stock from time to time, at its discretion. The company is not obligated to sell any shares, and it will pay the agent a commission of up to 3.0% of gross proceeds, so the program could dilute existing holders if used.
Sales Agreement with Leerink Partners LLC dated August 28, 2026, covering up to $50.0 million in common stock
Agent commission of up to 3.0% of gross proceeds from each sale
Shares offered under Form S-3 shelf registration declared effective December 8, 2025
Net proceeds intended for general corporate purposes, including working capital
Coherus Oncology declared a special dividend of contingent value rights (CVRs) to shareholders of record on September 30, 2026, with distribution on October 7, 2026. CVR holders may receive future cash payments only if the company sells or licenses its remaining biosimilar assets, and any payments depend on net cash proceeds actually received during a term ending October 7, 2028.
One CVR per common share held at 5:00 p.m. Eastern Time on September 30, 2026 (Record Date); distribution date October 7, 2026
Payments depend on net cash proceeds from the Legacy BioSim Assets, which include patents, royalties under an existing license, cell lines and related materials; no minimum payment is guaranteed
CVRs expire October 7, 2028 and are non-transferable and not listed; a Loan and Security Agreement dated August 12, 2026 with Innovatus Life Sciences Lending Fund I, L.P. restricts disposition of the assets and CVR payments
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Coherus Oncology, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →